← Leaderboards
Gordon D Rubenfeld
University Of Washington
$10,252,729
Attributed
$22,456,448
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2006–24$2.5M$1.9M$1.3M$625K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$22,456,448 · 5
By mechanism
UH3$8,723,851 · 1
U01$5,856,656 · 1
R01$4,702,892 · 1
UG3$2,341,858 · 1
P50$831,191 · 1
Top collaborators
- Michael J Boeckh10 shared
- Abhijit Prakash Limaye10 shared
- Renee D Stapleton6 shared
Most similar at University Of Washington
Same institution · by research overlap
- Michael Regnier$25,128,583
- Martin J Kushmerick$10,257,478
- Deirdre R. Meldrum$57,678,697
- Abhijit Prakash Limaye$10,475,049
- Wang Wang$4,107,549
Others in their field
Top investigators on “Lung Injury”
- Polly Chang · Sri International$53,674,299
- Asrar B. Malik · University Of Illinois At Chicago$44,050,753
- Edward E Morrisey · University Of Pennsylvania$36,050,545
- Boyd Taylor Thompson · Massachusetts General Hospital$33,582,267
- David Alan Schoenfeld · Massachusetts General Hospital$28,987,839
- Jahar Bhattacharya · St. Luke'S-Roosevelt Inst For Hlth Scis$28,655,382
Research focus
Lung InjuryMorbidity - Disease RateLungMechanical VentilationClinical TrialsAdultProphylactic TreatmentSepsisHerpesviridaeVirusDouble-Blind MethodImmunocompetentLength Of StayCytomegalovirusHealth ExpendituresPreventionGanciclovirFunctional DisorderCytomegalovirus InfectionsLung Injury, AcuteIncidenceAcute Respiratory FailureCaringPrevent
Grant awards (20)
1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis$2,170,027
UH3 · FY2024 · HL
1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis$2,120,121
UH3 · FY2023 · HL
1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis$2,216,758
UH3 · FY2022 · HL
1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis$1,503,461
UH3 · FY2021 · HL
1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis$713,484
UH3 · FY2021 · HL
1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis$2,341,858
UG3 · FY2020 · HL
A Randomzied Phase II Trial of CMV Prevention in Acute Lung Injury$370,684
U01 · FY2014 · HL
A Randomzied Phase II Trial of CMV Prevention in Acute Lung Injury$2,118,888
U01 · FY2012 · HL
A Randomzied Phase II Trial of CMV Prevention in Acute Lung Injury$2,126,770
U01 · FY2011 · HL
A Randomzied Phase II Trial of CMV Prevention in Acute Lung Injury$1,240,314
U01 · FY2010 · HL
Improving Ventilator Management and Preventing Injury to Patients with ARF$514,014
R01 · FY2009 · HL · contact PI
Improving Ventilator Management and Preventing Injury to Patients with ARF$492,337
R01 · FY2008 · HL · contact PI
Improving Ventilator Management and Preventing Injury to Patients with ARF$710,559
R01 · FY2007 · HL · contact PI
Improving long-term outcomes in survivors of ALI-ARDS$452,874
P50 · FY2007 · HL · contact PI
Improving Ventilator Management and Preventing Injury to Patients with ARF$690,916
R01 · FY2006 · HL · contact PI
Improving therapy of acute lung injury in the community$593,887
R01 · FY2004 · HL
Improving therapy of acute lung injury in the community$576,591
R01 · FY2003 · HL
Improving long-term outcomes in survivors of ALI-ARDS$378,317
P50 · FY2003 · HL
Improving therapy of acute lung injury in the community$559,795
R01 · FY2002 · HL
Improving therapy of acute lung injury in the community$564,793
R01 · FY2001 · HL